Showing results (251-260 of 486) with videos related to

Sort By:
Pageof 49
Expert Review of Pharmacoeconomics & Outcomes Research|February 7, 2022
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse eventsKit N Simpson, Michael J Fossler, Linda Wase, et al.
JMIR Formative Research|April 25, 2022
Feasibility of Using Electronic Health Records for Cascade Monitoring and Cost Estimates in Implementation Science Studies in the Adolescent Trials Network for HIV/AIDS InterventionsTyra Dark, Kit N Simpson, Sitaji Gurung, et al.
Pharmacoeconomics|June 6, 1997
Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infectionJ V Chancellor, A M Hill, C A Sabin, et al.
Clinical Drug Investigation|December 21, 2006
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart diseaseKit N Simpson, Michelle P Luo, Elinor C Chumney, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|June 28, 2017
How Accurately Do Both Parents and Health Professionals Assess Overweight in Children?Ickpyo Hong, Cynthia Brown Dodds, Patty Coker-Bolt, et al.
American Journal of Obstetrics and Gynecology|August 6, 2023
Bilateral salpingo-oophorectomy at the time of benign hysterectomy among females with disabilities: a population-based cross-sectional studyNatalie V Scime, Hilary K Brown, Amy Metcalfe, et al.
Academic Pediatrics|June 13, 2021
Increase in Mental Health Diagnoses Among Youth With Nonfatal Firearm InjuriesElizabeth R Oddo, Lizmarie Maldonado, Ashley B Hink, et al.
BMC Nephrology|July 12, 2014
Health care provider perception of chronic kidney disease: knowledge and behavior among African American patientsAbby S Kazley, Emily E Johnson, Kit N Simpson, et al.
HIV Clinical Trials|November 25, 2004
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infectionKit N Simpson, Michelle P Luo, Elinor Chumney, et al.
International Journal of Technology Assessment in Health Care|January 13, 2001
Measuring the effect of clinical guidelines on patient outcomesD A Marshall, K N Simpson, E C Norton, et al.
Pageof 49